The autophagy receptor NDP52 recruits the E3 ligase ASB2 to mediate NOX4 degradation, suppressing cardiomyocyte ferroptosis and ameliorating heart failure
Abstract
BACKGROUND: Heart failure (HF) is characterized by cardiomyocyte loss. While ferroptosis driven by NOX4 contributes to HF, how autophagy regulates NOX4 stability remains unclear.
METHODS: Using in vitro (isoproterenol-induced) and in vivo (TAC-induced) HF models, we combined pharmacological and genetic approaches with co-IP and molecular docking to investigate the autophagy-NOX4 axis.
RESULTS: We identified a novel pathway wherein autophagy activation prompts the receptor NDP52 to bind NOX4 and recruit the E3 ligase ASB2, mediating K48-linked ubiquitination and autophagic degradation of NOX4. This process suppressed ferroptosis and ameliorated cardiomyocyte injury. The NOX4 inhibitor GLX351322, alone or combined with the autophagy activator metformin, conferred significant cardioprotection in vivo.
CONCLUSION: Our findings reveal the 'autophagy-NDP52-ASB2-NOX4' axis as a crucial mechanism coupling autophagy to ferroptosis in HF, highlighting its therapeutic potential.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.